Werewolf Therapeutics (HOWL) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079

Cancer, Immunotherapy, Interleukin, Interferon, IL-21, IL-18

Werewolf Therapeutics, Inc. is a biopharmaceutical company that focuses on developing innovative therapies designed to stimulate the body's immune system to combat cancer. By leveraging its proprietary PREDATOR platform, the company creates conditionally activated molecules that enhance both adaptive and innate immunity, addressing the limitations of traditional proinflammatory immune therapies.

The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule currently in Phase I/Ib clinical trials for the treatment of advanced or metastatic solid tumors. Another promising candidate is WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trials for the treatment of advanced or metastatic solid tumors and lymphoma.

In addition to these lead candidates, Werewolf Therapeutics is also developing a range of other innovative therapies, including JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer. The company is also working on WTX-712, an activated Interleukin-21 (IL-21) molecule, and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule, both of which are being developed for the treatment of cancer.

Founded in 2017, Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, and is committed to harnessing the power of the immune system to develop effective treatments for cancer. For more information, please visit their website at https://werewolftx.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Werewolf Therapeutics (HOWL) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Werewolf Therapeutics (HOWL) - Stock & Dividends

HOWL Stock Overview

Market Cap in USD 139m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2021-04-30

HOWL Stock Ratings

Growth 5y -42.9
Fundamental -59.0
Dividend -
Rel. Performance vs Sector -0.10
Analysts 4.67/5
Fair Price Momentum 2.33 USD
Fair Price DCF -

HOWL Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

HOWL Growth Ratios

Growth 12m 2.13%
Growth Correlation 12m 38%
Growth Correlation 3m -62%
CAGR 5y -42.08%
CAGR/Mean DD 5y -0.63
Sharpe Ratio 12m -0.03
Alpha vs SP500 12m -29.98
Beta vs SP500 5y weekly 1.21
ValueRay RSI 14.74
Volatility GJR Garch 1y 109.18%
Price / SMA 50 -40.98%
Price / SMA 200 -32.24%
Current Volume 334k
Average Volume 20d 242.7k

External Links for HOWL Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of HOWL stocks?
As of June 22, 2024, the stock is trading at USD 2.88 with a total of 334,033 shares traded.
Over the past week, the price has changed by -4.32%, over one month by -42.40%, over three months by -50.77% and over the past year by +2.49%.
What are the forecast for HOWL stock price target?
According to ValueRays Forecast Model, HOWL Werewolf Therapeutics will be worth about 2.6 in June 2025. The stock is currently trading at 2.88. This means that the stock has a potential downside of -9.03%.
Issuer Forecast Upside
Wallstreet Target Price 12.5 334
Analysts Target Price 12.2 324
ValueRay Target Price 2.6 -9.03